Selected Publications
In PubMed (56):
http://www.ncbi.nlm.nih.gov/pubmed/?term=Molfino+N
Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. Molfino NA, Kuna P, Leff JA, Oh CK, Singh D, Chernow M, Sutton B, Yarranton G. BMJ Open. 2016 Jan 6;6(1):
Discriminating sputum-eosinophilic asthma: Accuracy of cutoffs in blood eosinophil measurements versus a composite index, ELEN. Khatry DB, Gossage DL, Geba GP, Parker JM, Jarjour NN, Busse WW, Molfino NA. J Allergy Clin Immunol. 2015 Sep;136(3):812-814.e2
The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study. Schmidt SA, Johansen MB, Olsen M, Xu X, Parker JM, Molfino NA, Lash TL, Sørensen HT, Christiansen CF. BMJ Open. 2014 Dec 19;4(12):
A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, Fiening JP, Kim K, Molfino NA. Am J Emerg Med. 2014 Oct 5.
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG. Lancet Respir Med. 2014 Nov;2(11):879-90.
A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA. Respir Res. 2013 Sep 19;14(1):93
Recent therapeutic breakthroughs in respiratory medicine. Molfino NA. Expert Rev Respir Med. 2013 Aug;7(4):331-3.
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA. J Allergy Clin Immunol. 2013 Jul 15.
Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based Danish cohort study. Johannesdottir SA, Christiansen CF, Johansen MB, Olsen M, Xu X, Parker JM, Molfino NA, Lash TL, Fryzek JP. J Med Econ. 2013 Jul;16(7):897-906.
Challenge models to assess new therapies in chronic obstructive pulmonary disease. van der Merwe R, Molfino NA. Int J Chron Obstruct Pulmon Dis. 2012;7:597-605.
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, Molfino NA. Eur Respir J. 2013 Feb;41(2):330-8.
Targeting of eosinophils in asthma. Molfino NA. Expert Opin Biol Ther. 2012 Jul;12(7):807-9.
Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Clin Exp Allergy. 2012 May;42(5):712-37
Smoking and idiopathic pulmonary fibrosis. Oh CK, Murray LA, Molfino NA. Pulm Med. 2012;2012:808260
Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma. Oh CK, Raible D, Geba GP, Molfino NA. Inflamm Allergy Drug Targets. 2011 Jun;10(3):180-6.
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Molfino NA; MEDI-528 Clinical Trials Group. BMC Pulm Med. 2011 Feb 28;11:14.
Brain magnetic resonance imaging in adults with asthma. Parker J, Wolansky LJ, Khatry D, Geba GP, Molfino NA. Contemp Clin Trials. 2011 Jan;32(1):86-9.
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ. J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, Geba GP, Molfino NA. J Allergy Clin Immunol. 2010 Jun;125(6):1237-1244
An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. Oh CK, Faggioni R, Jin F, Roskos LK, Wang B, Birrell C, Wilson R, Molfino NA. Br J Clin Pharmacol. 2010 Jun;69(6):645-55
Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Oh CK, Geba GP, Molfino NA. Eur Respir Rev. 2010 Mar;19(115):46-54
A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. BMC Pulm Med. 2010 Jan 8;10:3
Increased vagal airway tone in fatal asthma. Molfino NA. Med Hypotheses. 2010 Mar;74(3):521-3
Gene-environment interactions in chronic obstructive pulmonary disease. Molfino NA, Coyle AJ. Int J Chron Obstruct Pulmon Dis. 2008;3(3):491-7.
Genetic predisposition to accelerated decline of lung function in COPD. Molfino NA. Int J Chron Obstruct Pulmon Dis. 2007;2(2):117-9.
Current thinking on genetics of chronic obstructive pulmonary disease. Molfino NA. Curr Opin Pulm Med. 2007 Mar;13(2):107-13
Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies. Molfino NA, Jeffery PK. Pulm Pharmacol Ther. 2007;20(5):462-72
A meta-analysis on the efficacy of oral theophylline in patients with stable COPD. Molfino NA, Zhang P. Int J Chron Obstruct Pulmon Dis. 2006;1(3):261-6.
Drugs in clinical development for chronic obstructive pulmonary disease. Molfino NA. Respiration. 2005 Jan-Feb;72(1):105-12.
Trends in pharmacotherapy for chronic airflow limitation in Argentina: 1992-2002. Molfino NA. Medicina (B Aires). 2004;64(5):407-12.
Treatment of patients with chronic obstructive pulmonary disease (COPD) by primary care physicians. Molfino NA. Medicina (B Aires). 2004;64(5):445-54.
Lung function evolution and respiratory symptoms. Molfino NA. Arch Bronconeumol. 2004 Oct;40(10):429-30.
Genetics of COPD. Molfino NA. Chest. 2004 May;125(5):1929-40.
Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. De Feo LG, Schottlender J, Martelli NA, Molfino NA. Muscle Nerve. 2002 Jul;26(1):31-6
Eradication of multiple myeloma and breast cancer cells by TH9402-mediated photodynamic therapy: implication for clinical ex vivo purging of autologous stem cell transplants. Brasseur N, Ménard I, Forget A, el Jastimi R, Hamel R, Molfino NA, van Lier JE. Photochem Photobiol. 2000 Dec;72(6):780-7
Risk factors versus mechanisms of death in subjects with asthma. Molfino NA. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1355-6.
Effect of inhaled furosemide in acute asthma. Pendino JC, Nannini LJ, Chapman KR, Slutsky A, Molfino NA. J Asthma. 1998;35(1):89-93.
Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder. Raimondi AC, Schottlender J, Lombardi D, Molfino NA. Chest. 1997 Jul;112(1):24-8
Analysis of the T cell receptor Vgamma region gene repertoire in bronchoalveolar lavage (BAL) and peripheral blood of atopic asthmatics and healthy subjects. Molfino NA, Doherty PJ, Suurmann IL, Yang SX, Kesten S, Chapman KR, Slutsky AS. Clin Exp Immunol. 1996 Apr;104(1):144-53.
Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Newhouse MT, Chapman KR, McCallum AL, Abboud RT, Bowie DM, Hodder RV, Paré PD, Mesic-Fuchs H, Molfino NA. Chest. 1996 Sep;110(3):595-603
Tracheobronchial constriction in asthmatics induced by isocapnic hyperventilation with dry cold air. Julià-Serdà G, Molfino NA, Califaretti N, Hoffstein V, Zamel N. Chest. 1996 Aug;110(2):404-10.
The effect of pre-exposure to 0.12 ppm of ozone on exercise-induced asthma. Fernandes AL, Molfino NA, McClean PA, Silverman F, Tarlo S, Raizenne M, Slutsky AS, Zamel N. Chest. 1994 Oct;106(4):1077-82.
Near-fatal asthma. Molfino NA, Slutsky AS. Eur Respir J. 1994 May;7(5):981-90
Trends in pharmacotherapy for chronic airflow limitation in Argentina: 1983-1990. Molfino NA, Nannini LJ Jr, Chapman KR, Slutsky AS. Medicina (B Aires). 1994;54(2):103-9.
Assessment of airway tone in asthma. Comparison between double lung transplant patients and healthy subjects. Molfino NA, Slutsky AS, Julià-Serdà G, Hoffstein V, Szalai JP, Chapman KR, Rebuck AS, Zamel N. Am Rev Respir Dis. 1993 Nov;148(5):1238-43
Molfino NA and Slutsky AS. Proceedings of the Conference on Asthma Deaths: Near-Fatal Asthma. Clinical and Experimental Allergy 1993; 23: 156-159.
Tracheobronchial dilation during isocapnic hypoxia in conscious humans. Julià-Serdà G, Molfino NA, Furlott HG, McClean PA, Rebuck AS, Hoffstein V, Slutsky AS, Zamel N, Chapman KR. J Appl Physiol. 1993 Oct;75(4):1728-33.
Heterogeneous airway tone in asthmatic subjects. Julia-Serda G, Molfino NA, Chapman KR, McClean PA, Zamel N, Slutsky AS, Hoffstein V. J Appl Physiol. 1992 Dec;73(6):2328-32
Echogram of the upper airway. Julià-Serdà G, Molfino NA, Zamel N. Med Clin (Barc). 1992 Oct 10;99(11):425-9
Changes in cross-sectional airway areas induced by methacholine, histamine, and LTC4 in asthmatic subjects. Molfino NA, Slutsky AS, Hoffstein V, McClean PA, Rebuck AS, Drazen JM, Zamel N. Am Rev Respir Dis. 1992 Sep;146(3):577-80
The effects of air pollution on allergic bronchial responsiveness. Molfino NA, Slutsky AS, Zamel N. Clin Exp Allergy. 1992 Jul;22(7):667-72.
The fatality-prone asthmatic patient. Follow-up study after near-fatal attacks. Molfino NA, Nannini LJ, Rebuck AS, Slutsky AS. Chest. 1992 Mar;101(3):621-3
The effects of air pollution on atopic asthma. Molfino NA. Medicina (B Aires). 1992;52(4):363-7
Effect of low concentrations of ozone on inhaled allergen responses in asthmatic subjects. Molfino NA, Wright SC, Katz I, Tarlo S, Silverman F, McClean PA, Szalai JP, Raizenne M, Slutsky AS, Zamel N. Lancet. 1991 Jul 27;338(8761):199-203
Respiratory arrest in near-fatal asthma. Molfino NA, Nannini LJ, Martelli AN, Slutsky AS. N Engl J Med. 1991 Jan 31;324(5):285-8.
Artifacts in measuring airway areas by acoustic reflections. Molfino N, Zamel N, Hoffstein V, Fredberg J. Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1465-6
Other publications (10):
Oh CK and Molfino NA, Hereditary Pulmonary Emphysema in Emery and Rimoin’s Principles and Practice of Medical Genetics, 6th Edition, 2011 (book chapter)
Oh CK, and Molfino NA, Genetics of COPD in Emphysema: Causes, Symptoms and Prevention (book chapter) 2011
Busse WW, Molfino NA, Kolbeck R. IL-5 Receptor directed strategies. (book chapter) 2011.
Humbles A, Molfino NA et al. Monoclonal antibody therapy directed against interleukin-9: MEDI 528.
Chapter in New Drugs and Targets for Asthma and COPD (2010); vol 39: 137-140.
Molfino NA. New anti-inflammatory therapies for the treatment of COPD. Drug Discovery Today: Therapeutic Strategies 2008; 5 (2): 93-96
Molfino NA. Asma casi fatal; chapter in Medicina Intensiva; edited by C. Lovesio; 2001 El Ateneo, Buenos Aires: p. 66-77.
Molfino NA. Near-Fatal Asthma; chapter in Acute Asthma; edited by J. Hall, T. Coldbridge; C. Rodrigo and G. Rodrigo; 2000 McGraw-Hill, Chicago
Molfino, NA. The role of T-cells in asthma. Practical Allergy & Immunology 1994; 9 (4): 157-163.
Molfino NA. Averting the fatal asthma attack. Emergency Medicine 1991; 23(15): 45-50.
Molfino NA and Zamel N. Clinical Interpretation of bronchial hyperresponsiveness. Respirology 1990; 1(4): 15.
Website last updated January 2016